Building healthier futures powered by thoughtful science
We are a highly focused, research-driven biopharmaceutical company working in rare diseases. We're exploring the potential of cutting-edge science as a subsidiary of Nippon Shinyaku Co., Ltd. In Japan.
Advancing rare disease research
Inspired by our own families, as well as the individuals we aim to provide with treatment, NS Pharma is conducting advanced research in rare diseases, including exon-skipping technology, to offer new, effective treatment options for Duchenne. We’re also developing JAK1 inhibition for the potential treatment of eosinophilic granulomatosis with polyangiitis (EGPA).
Therapeutic areas
NS Pharma is working to have an important impact on the lives of patients with rare diseases. Our therapeutic areas encompass neurological diseases and inflammatory diseases.
Scientific approaches
Harnessing the power of innovative science can help bring new treatments to patients with rare diseases. NS Pharma is developing therapies through exon-skipping, cell therapy and JAK1 inhibition technology.
Therapeutic areas
NS Pharma is working to have an important impact on the lives of patients with rare diseases. Our therapeutic areas encompass neurological diseases and inflammatory diseases.
Scientific approaches
Harnessing the power of innovative science can help bring new treatments to patients with rare diseases. NS Pharma is developing therapies through exon-skipping, cell therapy and JAK1 inhibition technology.
From our blog
Press Release / March 27, 2025
Positive Data Showing Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Released at 2025 MDA Conference
Press Release / March 6, 2025
FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment
News / February 7, 2025
NS Pharma and MiNA Therapeutics: Meeting Unmet Medical Needs Through Partnership and Co-creation
Press Release / March 27, 2025
Positive Data Showing Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Released at 2025 MDA Conference
Press Release / March 6, 2025
FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment
News / February 7, 2025
NS Pharma and MiNA Therapeutics: Meeting Unmet Medical Needs Through Partnership and Co-creation
We're thrilled to share the latest results from the HOPE-2 clinical trial, showing promising long-term efficacy of #Deramiocel in treating #Duchenne muscular dystrophy cardiomyopathy.
Read the press release: https://ow.ly/bMEa50VpPK7 https://x.com/NSPharmaInc/status/1905286589363691924/photo/1
The NSP team had an incredible time at the #MDAConference, connecting with experts, advocates, and families who share our commitment to the neuromuscular community.
Thank you to everyone who stopped by to chat with us! Until next time!